Aardvark (AARD) | Financial Analysis & Statements
Aardvark Therapeutics Inc. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-18.7M
Net Income
-17.6M
Balance Sheet Metrics
Total Assets
117.2M
Total Liabilities
10.5M
Shareholders Equity
106.6M
Debt to Equity
0.10
Cash Flow Metrics
Operating Cash Flow
-18.4M
Free Cash Flow
-16.8M
Revenue & Profitability Trend
Aardvark Income Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - |
| Gross Profit | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | ||||
| Research & Development | 48.9M | 17.4M | 4.5M | 7.2M |
| Selling, General & Administrative | 13.8M | 5.3M | 2.2M | 2.7M |
| Other Operating Expenses | - | - | - | - |
| Total Operating Expenses | 62.7M | 22.7M | 6.7M | 9.9M |
| Operating Income | -62.7M | -22.7M | -7.4M | -10.4M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | ||||
| Interest Income | 5.1M | 2.4M | 1.4M | 120.0K |
| Interest Expense | - | - | - | - |
| Other Non-Operating Income | -5.0K | -334.0K | -1.2M | -3.3M |
| Pre-tax Income | -57.6M | -20.6M | -7.2M | -13.6M |
| Income Tax | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -57.6M | -20.6M | -7.2M | -13.6M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | ||||
| EBITDA | -62.7M | -22.3M | -6.1M | -6.9M |
| EPS (Basic) | $-2.93 | $-0.96 | $-0.56 | $-0.12 |
| EPS (Diluted) | $-2.93 | $-0.96 | $-0.56 | $-0.12 |
| Basic Shares Outstanding | 19624626 | 21384377 | 12909267 | 109393427 |
| Diluted Shares Outstanding | 19624626 | 21384377 | 12909267 | 109393427 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Aardvark Balance Sheet From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Assets | ||||
| Current Assets | ||||
| Cash & Equivalents | 47.1M | 61.6M | 9.7M | 15.6M |
| Short-term Investments | 63.0M | 12.0M | 254.0K | 546.0K |
| Accounts Receivable | - | - | - | - |
| Inventory | - | - | - | - |
| Other Current Assets | 1.9M | 160.0K | 127.0K | 70.0K |
| Total Current Assets | 111.9M | 74.1M | 10.4M | 16.5M |
| Non-Current Assets | ||||
| Property, Plant & Equipment | 355.0K | 735.0K | 155.0K | 252.0K |
| Goodwill | - | - | - | - |
| Intangible Assets | - | - | - | - |
| Long-term Investments | - | - | - | - |
| Other Non-Current Assets | 4.9M | 2.6M | 13.0K | 14.0K |
| Total Non-Current Assets | 5.3M | 3.4M | 168.0K | 266.0K |
| Total Assets | 117.2M | 77.5M | 10.5M | 16.8M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | 2.1M | 2.3M | 1.0M | 259.0K |
| Short-term Debt | 441.0K | 338.0K | 112.0K | 100.0K |
| Current Portion of Long-term Debt | - | - | - | - |
| Other Current Liabilities | - | - | - | - |
| Total Current Liabilities | 10.5M | 4.9M | 1.4M | 595.0K |
| Non-Current Liabilities | ||||
| Long-term Debt | 0 | 441.0K | 50.0K | 162.0K |
| Deferred Tax Liabilities | - | - | - | - |
| Other Non-Current Liabilities | - | 26.0K | 2.0K | 19.0K |
| Total Non-Current Liabilities | 0 | 127.2M | 44.0M | 44.1M |
| Total Liabilities | 10.5M | 132.2M | 45.3M | 44.7M |
| Equity | ||||
| Common Stock | 0 | 0 | 0 | 0 |
| Retained Earnings | -115.9M | -58.3M | -37.7M | -30.5M |
| Treasury Stock | - | - | - | - |
| Other Equity | - | - | - | - |
| Total Shareholders Equity | 106.6M | -54.6M | -34.8M | -27.9M |
| Key Metrics | ||||
| Total Debt | 441.0K | 779.0K | 162.0K | 262.0K |
| Working Capital | 101.3M | 69.2M | 9.0M | 15.9M |
Balance Sheet Composition
Aardvark Cash Flow Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | -57.6M | -20.6M | -7.2M | -13.6M |
| Depreciation & Amortization | 36.0K | 16.0K | 97.0K | 110.0K |
| Stock-Based Compensation | 3.9M | 439.0K | 313.0K | 412.0K |
| Working Capital Changes | -99.0K | 600.0K | 676.0K | -70.0K |
| Operating Cash Flow | -53.3M | -19.3M | -6.1M | -12.1M |
| Investing Activities | ||||
| Capital Expenditures | -95.0K | -109.0K | - | - |
| Acquisitions | - | - | - | - |
| Investment Purchases | -129.6M | -11.9M | - | - |
| Investment Sales | 80.0M | - | - | - |
| Investing Cash Flow | -49.7M | -12.0M | - | -1.0M |
| Financing Activities | ||||
| Share Repurchases | - | - | - | - |
| Dividends Paid | - | - | - | - |
| Debt Issuance | - | - | - | - |
| Debt Repayment | - | - | - | - |
| Financing Cash Flow | 88.7M | 81.7M | 0 | 225.0K |
| Free Cash Flow | -54.3M | -18.2M | -5.8M | -10.5M |
| Net Change in Cash | -14.3M | 50.4M | -6.1M | -12.9M |
Cash Flow Trend
Aardvark Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-1.83
Forward P/E
-1.55
Price to Book
1.10
PEG Ratio
-1.55
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-64.44%
Return on Assets
-40.27%
Financial Health
Current Ratio
10.61
Debt to Equity
0.41
Per Share Data
EPS (TTM)
$-2.79
Book Value per Share
$4.89
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| AARD | 117.2M | -1.83 | 1.10 | -64.44% | 0.00% | 0.41 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Adagene | 243.8M | - | 4.95 | -34.39% | -229.56% | 12.07 |
| Orchestra BioMed | 242.9M | - | 4.48 | -109.41% | -157.40% | 25.17 |
| Third Harmonic Bio | 242.8M | 12.46 | 0.89 | -19.94% | 0.00% | 1.10 |
Financial data is updated regularly. All figures are in the company's reporting currency.






